- Home
- MRSN
as 01-17-2025 4:00pm EST
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 252.0M | IPO Year: | 2017 |
| Target Price: | $6.00 | AVG Volume (30 days): | 7.3M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.56 - $6.28 | Next Earning Date: | 02-26-2025 |
| Revenue: | $34,837,000 | Revenue Growth: | -14.70% |
| Revenue Growth (this year): | -12.14% | Revenue Growth (next year): | -14.29% |
Stock Insider Trading Activity of Mersana Therapeutics Inc. (MRSN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lowinger Timothy B | MRSN | SVP, Chief Sci.&Tech. Officer | Jan 14 '25 | Sell | $0.63 | 1,794 | $1,130.22 | 245,930 | |
| Mandelia Ashish | MRSN | VP, Chief Accounting Officer | Jan 14 '25 | Sell | $0.63 | 1,791 | $1,128.33 | 52,388 | |
| Carvajal Alejandra | MRSN | SVP, Chief Legal Officer | Jan 14 '25 | Sell | $0.63 | 952 | $599.76 | 70,892 | |
| DeSchuytner Brian | MRSN | SVP, COO & CFO | Jan 14 '25 | Sell | $0.63 | 2,331 | $1,468.53 | 109,030 | |
| Lowinger Timothy B | MRSN | SVP, Chief Sci.&Tech. Officer | Jan 13 '25 | Sell | $0.66 | 3,483 | $2,298.78 | 245,930 | |
| Mandelia Ashish | MRSN | VP, Chief Accounting Officer | Jan 13 '25 | Sell | $0.66 | 1,007 | $664.62 | 52,388 | |
| Carvajal Alejandra | MRSN | SVP, Chief Legal Officer | Jan 13 '25 | Sell | $0.66 | 3,330 | $2,197.80 | 70,892 | |
| DeSchuytner Brian | MRSN | SVP, COO & CFO | Jan 13 '25 | Sell | $0.66 | 3,713 | $2,450.58 | 109,030 | |
| Bala Mohan | MRSN | SVP, Chief Development Officer | Oct 25 '24 | Sell | $1.90 | 1,884 | $3,579.60 | 54,731 |
Latest Mersana Therapeutics Inc. News
MRSN Breaking Stock News: Dive into MRSN Ticker-Specific Updates for Smart Investing
MT Newswires
8 days ago
Wedbush Cuts Price Target on Mersana Therapeutics to $4 From $7, Keeps Outperform Rating
Benzinga
8 days ago
Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?
MT Newswires
9 days ago
Mersana Therapeutics' XMT-1660 Gains Additional US FDA Fast Track Designation
MT Newswires
9 days ago
Mersana Therapeutics Says Initial Data From Cancer Drug Trial Shows Promise, Shares Rise Premarket
GlobeNewswire
9 days ago
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
GlobeNewswire
9 days ago
Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer
GuruFocus.com
2 months ago
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
Thomson Reuters StreetEvents
2 months ago
Q3 2024 Mersana Therapeutics Inc Earnings Call
Compare MRSN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRSN Mersana Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.